TNFRSF4 and breast carcinoma: Murata et al. showed that the combination of the OX40 antibody and GM-CSF secreting tumor cell vaccine induced a specific CD8+ T cell response, thereby inhibiting tumor growth in breast cancer mice (Murata et al. 2006).